Featured Intelligence

A gene therapy for a specific inherited form of deafness has crossed into real, approved medicine, and the results are genuinely striking. In clinical trials, roughly four out of five children treated for OTOF-related hearing loss, a condition caused

NAD+ boosting supplements have been sold on the promise of slowing cellular aging for years, built largely on animal research and plausible biochemistry rather than rigorous human evidence. That changed somewhat this year with a randomized controlled trial that, for

Roughly one in five people carry high levels of lipoprotein(a), a genetically determined particle in the blood linked to heart attack and stroke risk that, unlike standard cholesterol, cannot be meaningfully lowered through diet, exercise, or existing statin drugs.

Age-related muscle loss, the gradual decline in strength and lean mass that makes falls, frailty, and lost independence more likely later in life, has no approved drug treatment anywhere in the world. Bimagrumab, one of the most closely watched

Gut bacteria therapy has quietly become one of the few areas of microbiome science with real, FDA-approved treatments already in use, not just promising early research. Two prescription therapies are now approved specifically to prevent recurrent C. difficile infection,

For several years, pig-to-human organ transplants existed only as isolated, emergency-authorized cases, each one a single data point rather than part of an organized study. That changed when the first formal, multicenter clinical trial of a gene-

A single blood draw that can flag signals for dozens of different cancers sounds like exactly the kind of tool a careful, proactive approach to health should want. Several versions of this technology, broadly called multi-cancer early detection tests,

Biological age testing has existed as a consumer product for years, often sold with confident marketing and little independent evidence behind the number it produces. That changed somewhat this year. A series of large, peer-reviewed studies has now validated

CRISPR gene editing already has an approved medicine on the market, but getting it means a hospital stay, chemotherapy-style conditioning, and a process that can take months. That is the reality behind Casgevy, the first CRISPR-based therapy ever